FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.
What happened
FDA inspected Northland Nuclear Medicine's PET drug manufacturing facility at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. FDA found the firm did not properly investigate more than 100 microbial recoveries in ISO 5 areas (the cleanest air zones, where sterile filling is done) between March 2024 and April 2026, stored environmental monitoring plates in a sporicidal solution that can kill the organisms the tests are meant to catch, and repeatedly lowered a yield limit instead of finding the root cause of failing batches. FDA called the firm's June 11, 2026 response inadequate and noted similar violations were discussed at a December 13, 2023 regulatory meeting.
What FDA found
The firm did not adequately investigate out-of-limit environmental monitoring results, identify the root cause of repeated microbial findings, or take effective corrective action.
21 CFR 212.20(d)Corrective actions for repeated low radiochemical yields were closed without effectiveness checks, and the firm lowered its yield limit rather than fixing the cause.
21 CFR 212.20(d)Environmental monitoring plates were stored in a container with sporicidal solution before and after sampling, which can suppress microbial growth and produce false negatives.
21 CFR 212.30(b)Smoke studies did not test airflow under dynamic conditions during actual filling and workstation operations.
21 CFR 212.30(b)The firm did not adequately disinfect equipment surfaces before aseptic manufacturing and had no written disinfection procedure for those surfaces.
21 CFR 212.30(b)
What FDA wants
FDA asks the firm to send a written response within 15 business days to CDER-OC-OMQ-Communications@fda.hhs.gov, citing FEI 3005334016 and ATTN: Compliance Officer Michael Klapal, with independent assessments of its environmental monitoring program, investigation system, quality unit, contamination hazards, and dynamic smoke studies plus remediation plans. FDA also recommends engaging a qualified CGMP consultant to audit the operation.
Who should pay attention
- hospitals and imaging centers that receive and administer PET drugs from this firm
- other PET drug producers and nuclear pharmacies using aseptic processing
- quality and compliance teams at sterile drug manufacturers with similar environmental monitoring practices
This is a summary. Read the original letter on fda.gov.